Evidence-Based Complementary and Alternative Medicine

Research Article

Fisetin Inhibits Osteoclast Differentiation via Downregulation of p38 and c-Fos-NFATc1 Signaling Pathways

Figure 1

Fisetin inhibits RANKL-mediated osteoclast differentiation. (a) Structure of fisetin. (b) BMM cells were cultured for 4 days in the presence of RANKL (5 ng/mL) and M-CSF (30 ng/mL) with the vehicle (DMSO) or fisetin. Multinucleated osteoclasts were visualized to red-colored giant cells by TRAP staining. (c) Total TRAP-positive multinucleated osteoclasts (TRAP + MNCs; left graph) and TRAP + MNCs with more than 3 nuclei ( 𝑁 > 3 ; right graph) were counted. ** 𝑃 < 0 . 0 1 ; *** 𝑃 < 0 . 0 0 1 (versus “the control”). (d) TRAP activity was measured. ### 𝑃 < 0 . 0 0 1 (versus “the negative control”). ** 𝑃 < 0 . 0 1 ; *** 𝑃 < 0 . 0 0 1 (versus “the positive control”). (e) After pretreatment with the vehicle (DMSO) or fisetin (5 μM) for 1 h, BMMs were treated with RANKL (5 ng/mL) for the indicated number of days, and then mRNA expression levels were analyzed by real-time PCR. * 𝑃 < 0 . 0 5 ; ** 𝑃 < 0 . 0 1 ; *** 𝑃 < 0 . 0 0 1 (versus “the vehicle control”). (f) Effect of fisetin on the viability of BMMs was evaluated by CCK-8 assay.
810563.fig.001a
(a)
810563.fig.001b
(b)
810563.fig.001c
(c)
810563.fig.001d
(d)
810563.fig.001e
(e)
810563.fig.001f
(f)